Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

_________________________________________________________

FORM 10-Q

_________________________________________________________

(Mark One)


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024


o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission File Number: 001-39781

_________________________________________________________

AbCellera Biologics Inc.

(Exact Name of Registrant as Specified in its Charter)

_________________________________________________________


British Columbia			Not Applicable
( State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
2215 Yukon Street Vancouver, BC			V5Y 0A1
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (604) 559-9005

_________________________________________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange on which registered

Common shares, no par value per share

ABCL

The Nasdaq Stock Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of October 31, 2024, the registrant had 295,366,280 common shares, no par value per share, outstanding.

Table of Contents


		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Loss and Comprehensive Loss	2
	Condensed Consolidated Statements of Stockholders’ Equity	3
	Condensed Consolidated Statements of Cash Flows	4
	Notes to Unaudited Condensed Consolidated Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25
Item 4.	Controls and Procedures	25
PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	26
Item 1A.	Risk Factors	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	76
Item 5.	Other Information	76
Item 6.	Exhibits	77
	Signatures	78

Summary of the Material and Other Risks Associated with Our Business

Our business is subject to numerous material and other risks and uncertainties. You should carefully consider the following information together with the other information appearing elsewhere in this Quarterly Report, including our financial statements and related notes hereto. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects. The risks and uncertainties described below may change over time and other risks and uncertainties, including those that we do not currently consider material, may impair our business. These risks include, but are not limited to, the following:

•We have incurred losses in certain years since inception, including in 2023 and 2024, and we may not be able to generate sufficient revenue to achieve profitability.

•Our quarterly and annual operating results have fluctuated significantly in the past and may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.

•Unstable market and economic conditions may have serious adverse consequences on our business, financial condition, and share price.

•Our commercial success depends on the quality of our antibody discovery and development engine and technological capabilities, the advancement of internal programs, and their acceptance by new and existing partners in our industry.

•Failure to execute our business strategy could adversely impact our growth and profitability.

•If we cannot maintain and expand current partnerships and enter new partnerships that generate discovery programs for antibodies, our business could be adversely affected.

•Development of a biological molecule is inherently uncertain, and it is possible that none of the antibody drug candidates discovered using our antibody discovery and development engine that are further developed by us or our partners will receive marketing approval or become viable commercial products, on a timely basis or at all.

•The failure of our partners to meet their contractual obligations to us could adversely affect our business.

•We may be unable to manage our current and future growth effectively, which could make it difficult to execute on our business strategy.

•We have invested, and expect to continue to invest, in research and development efforts that further enhance our technology and platform. Such investments in technology are inherently risky and may affect our operating results. If the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer.

•Our partners have significant discretion in determining when and whether to make announcements, if any, about the status of our partnerships, including about clinical developments and timelines for advancing collaborative programs with the antibodies that we have discovered, and the price of our common shares may decline as a result of announcements of unexpected results or developments.

•Our partners may not achieve projected discovery and development milestones and other anticipated key events in the expected timelines or at all, which could have an adverse impact on our business and could cause the price of our common shares to decline.

•We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.

•The life sciences and biotechnology platform technology market is highly competitive, and if we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue, or achieve profitability.

•Upgrading and integrating our business systems could result in implementation issues and business disruptions.

•If we are unable to obtain and maintain sufficient intellectual property protection for our technology, including our discovery and development engine, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies or a platform similar or identical to ours, and our ability to successfully sell our data packages may be impaired.

•If we fail to maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.

•Impairment charges pertaining to goodwill, identifiable intangible assets or other long-lived assets from our mergers and acquisitions could have an adverse non-cash accounting impact on our results of operations.

•Sales of a substantial number of our common shares in the public market could cause our share price to fall significantly, even if our business is doing well.

Investing in our common shares involves a high degree of risk. You should carefully consider the risks and uncertainties contained in Part II, Item 1A, Risk Factors, together with all other information in this Quarterly Report on Form 10-Q, including our consolidated financial statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as our other filings with the Securities and Exchange Commission, or the SEC, before investing in our common shares. Any of the risk factors we describe below under Part II, Item 1A, Risk Factors, could adversely affect our business, financial condition or results of operations. The market price of our common shares could decline if one or more of these risks or uncertainties were to occur, which may cause you to lose all or part of the money you paid to buy our common shares. Additional risks that are currently unknown to us or that we currently believe to be immaterial may also impair our business. Certain statements below are forward-looking statements. See “Forward-Looking Information” in this Quarterly Report on Form 10-Q.

iii

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

AbCellera Biologics Inc.

Condensed Consolidated Balance Sheets

(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)

(Unaudited)


	December 31, 2023		September 30, 2024
Assets
Current assets:
Cash and cash equivalents	$	133,320	$	126,640
Marketable securities	627,265		516,499
Total cash, cash equivalents, and marketable securities	760,585		643,139
Accounts and accrued receivable	30,590		31,373
Restricted cash	25,000		25,000
Other current assets	55,810		43,371
Total current assets	871,985		742,883
Long-term assets:
Property and equipment, net	287,696		331,263
Intangible assets, net	120,425		52,577
Goodwill	47,806		47,806
Investments in equity accounted investees	65,938		84,084
Other long-term assets	94,244		134,215
Total long-term assets	616,109		649,945
Total assets	$	1,488,094	$	1,392,828
Liabilities and shareholders' equity
Current liabilities:
Accounts payable and other current liabilities	$	49,580	$	53,773
Contingent consideration payable	50,475		20,217
Deferred revenue	18,958		5,578
Total current liabilities	119,013		79,568
Long-term liabilities:
Operating lease liability	71,222		66,274
Deferred revenue	8,195		8,100
Deferred government contributions	95,915		142,046
Contingent consideration payable	4,913		4,441
Deferred tax liability	30,612		12,781
Other long-term liabilities	5,906		1,524
Total long-term liabilities	216,763		235,166
Total liabilities	335,776		314,734
Commitments and contingencies
Shareholders' equity:
Common shares: no par value, unlimited authorized shares at December 31, 2023 and September 30, 2024: 290,824,970 and 295,157,474 shares issued and outstanding at December 31, 2023 and September 30, 2024, respectively	753,199		772,832
Additional paid-in capital	121,052		155,354
Accumulated other comprehensive loss	(1,720)		(1,232)
Accumulated earnings	279,787		151,140
Total shareholders' equity	1,152,318		1,078,094
Total liabilities and shareholders' equity	$	1,488,094	$	1,392,828

The accompanying notes are an integral part of these condensed consolidated financial statements.

AbCellera Biologics Inc.

Condensed Consolidated Statements of Loss and Comprehensive Loss

(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data.)

(Unaudited)


	Three months ended September 30,				Nine months ended September 30,
	2023		2024		2023		2024
Revenue:
Research fees	$	6,413	$	6,289	$	26,812	$	21,516
Licensing revenue	186		218		784		767
Milestone payments	–		–		1,250		1,500
Total revenue	6,599		6,507		28,846		23,783
Operating expenses:
Research and development(1)	37,917		40,969		127,036		121,183
Sales and marketing(1)	3,468		3,135		11,080		9,635
General and administrative(1)	14,369		19,147		45,025		56,691
Depreciation, amortization, and impairment	5,735		36,919		16,859		78,285
Total operating expenses	61,489		100,170		200,000		265,794
Loss from operations	(54,890)		(93,663)		(171,154)		(242,011)
Other income:
Interest income	(10,740)		(9,603)		(31,278)		(29,805)
Grants and incentives	(2,828)		(3,491)		(10,779)		(10,076)
Other income	(2,046)		(17,937)		(3,670)		(48,564)
Total other income	(15,614)		(31,031)		(45,727)		(88,445)
Net loss before income tax	(39,276)		(62,632)		(125,427)		(153,566)
Income tax recovery	(10,666)		(11,525)		(26,179)		(24,919)
Net loss	$	(28,610)	$	(51,107)	$	(99,248)	$	(128,647)
Foreign currency translation adjustment	439		841		(69)		488
Comprehensive loss	$	(28,171)	$	(50,266)	$	(99,317)	$	(128,159)

Net loss per share
Basic	$	(0.10)	$	(0.17)	$	(0.34)	$	(0.44)
Diluted	$	(0.10)	$	(0.17)	$	(0.34)	$	(0.44)
Weighted-average common shares outstanding
Basic	289,496,841		294,851,945		288,750,387		293,930,702
Diluted	289,496,841		294,851,945		288,750,387		293,930,702

The accompanying notes are an integral part of these condensed consolidated financial statements.

1Exclusive of depreciation, amortization, and impairment

AbCellera Biologics Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)

(Unaudited)


	Common Shares			Additional Paid-in Capital		Accumulated Earnings		Accumulated Other Comprehensive Loss		Total Shareholders' Equity
	Shares	Amount
Balances as of December 31, 2023	290,824,970	$	753,199	$	121,052	$	279,787	$	(1,720)	$	1,152,318
Shares issued and restricted stock units ("RSUs") vested under stock option plan	2,796,342	11,363		(10,471)		–		–		892
Stock-based compensation expense	–	–		17,409		–		–		17,409
Foreign currency translation adjustment	–	–		–		–		(96)		(96)
Net loss	–	–		–		(40,610)		–		(40,610)
Balances as of March 31, 2024	293,621,312	$	764,562	$	127,990	$	239,177	$	(1,816)	$	1,129,913
Shares issued and restricted stock units ("RSUs") vested under stock option plan	1,044,220	5,404		(4,944)		–		–		460
Stock-based compensation expense	–	–		17,782		–		–		17,782
Foreign currency translation adjustment	–	–		–		–		(257)		(257)
Net loss	–	–		–		(36,930)		–		(36,930)
Balances as of June 30, 2024	294,665,532	$	769,966	$	140,828	$	202,247	$	(2,073)	$	1,110,968
Shares issued and restricted stock units ("RSUs") vested under stock option plan	491,942	2,866		(2,638)		–		–		228
Stock-based compensation expense	–	–		17,164		–		–		17,164
Foreign currency translation adjustment	–	–		–		–		841		841
Net loss	–	–		–		(51,107)		–		(51,107)
Balances as of September 30, 2024	295,157,474	$	772,832	$	155,354	$	151,140	$	(1,232)	$	1,078,094


	Common Shares			Additional Paid-in Capital		Accumulated Earnings		Accumulated Other Comprehensive Loss		Total Shareholders' Equity
	Shares	Amount
Balances as of December 31, 2022	286,851,595	$	734,365	$	74,118	$	426,185	$	(1,391)	$	1,233,277
Shares issued and restricted stock units ("RSUs") vested under stock option plan	1,574,919	8,451		(7,962)		–		–		489
Share-based compensation expense	–	–		15,474		–		–		15,474
Foreign currency translation adjustment	–	–		–		–		(630)		(630)
Net loss	–	–		–		(40,110)		–		(40,110)
Balances as of March 31, 2023	288,426,514	$	742,816	$	81,630	$	386,075	$	(2,021)	$	1,208,500
Shares issued and restricted stock units ("RSUs") vested under stock option plan	762,955	1,940		(1,606)		–		–		334
Share-based compensation expense	–	–		16,399		–		–		16,399
Foreign currency translation adjustment	–	–		–		–		122		122
Net loss	–	–		–		(30,528)		–		(30,528)
Balances as of June 30, 2023	289,189,469	$	744,756	$	96,423	$	355,547	$	(1,899)	$	1,194,827
Shares issued and restricted stock units ("RSUs") vested under stock option plan	588,185	3,158		(2,901)		–		–		257
Share-based compensation expense	–	–		15,862		–		–		15,862
Foreign currency translation adjustment	–	–		–		–		439		439
Net loss	–	–		–		(28,610)		–		(28,610)
Balances as of September 30, 2023	289,777,654	$	747,914	$	109,384	$	326,937	$	(1,460)	$	1,182,775

The accompanying notes are an integral part of these condensed consolidated financial statements.

AbCellera Biologics Inc.

Condensed Consolidated Statements of Cash Flows

(Expressed in thousands of U.S. dollars.)

(Unaudited)


	Nine months ended September 30,
	2023		2024
Cash flows from operating activities:
Net loss	$	(99,248)	$	(128,647)
Cash flows from operating activities:
Depreciation of property and equipment	8,874		10,437
Amortization and impairment of intangible assets	7,985		67,848
Amortization of operating lease right-of-use assets	4,926		4,813
Stock-based compensation	47,735		52,355
Fair value gain on contingent consideration and investments	–		(48,727)
Deferred income tax and other	(6,354)		(17,891)
Changes in operating assets and liabilities:
Research fees and grants receivable	(35,495)		(54,258)
Accrued royalties receivable	9,273		–
Income taxes payable (receivable)	28,685		(8,709)
Accounts payable and accrued liabilities	(1,852)		4,018
Deferred revenue	(7,238)		(13,474)
Accrued royalties payable	(16,253)		–
Deferred grant income	30,377		30,671
Other assets	4,319		1,008
Net cash used in operating activities	(24,266)		(100,556)
Cash flows from investing activities:
Purchases of property and equipment	(62,516)		(62,766)
Purchase of marketable securities	(744,674)		(612,249)
Proceeds from marketable securities	642,913		735,989
Receipt of grant funding	15,023		29,150
Long-term investments and other assets	(37,317)		13,538
Investment in equity accounted investees	(10,214)		(17,956)
Net cash provided by (used in) investing activities	(196,785)		85,706
Cash flows from financing activities:
Payment of liability for in-licensing agreement and other	(1,049)		(552)
Proceeds from long-term liabilities	6,560		7,599
Proceeds from exercise of stock options	1,080		1,580
Net cash provided by financing activities	6,591		8,627
Effect of exchange rate changes on cash and cash equivalents	(479)		(457)
Decrease in cash and cash equivalents	(214,939)		(6,680)
Cash and cash equivalents and restricted cash, beginning of period	414,651		160,610
Cash and cash equivalents and restricted cash, end of period	$	199,712	$	153,930
Restricted cash included in other assets	2,290		2,290
Total cash, cash equivalents, and restricted cash shown on the balance sheet	$	197,422	$	151,640
Supplemental disclosure of non-cash investing and financing activities
Property and equipment in accounts payable	12,948		15,989
Right-of-use assets obtained in exchange for operating lease obligation	3,586		2,232

The accompanying notes are an integral part of these condensed consolidated financial statements.

AbCellera Biologics Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)

(Unaudited)

1. Nature of operations

AbCellera Biologics Inc.’s (the “Company”) mission is to bring better antibody drugs to patients faster, solve long-standing problems, and transform how antibody drugs are discovered. The Company aims to bring antibody therapeutics from target to clinic by combining expertise, technologies, and infrastructure to build an engine for antibody drug discovery and development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty (and equivalent) stakes in future antibody drugs and to develop its own pipeline of future antibody drugs. The Company partners with companies of all sizes - from innovative biotechnology companies to leading pharmaceutical companies - propelling programs to the clinic, together.

2. Basis of presentation

The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Accordingly, the year-end condensed consolidated financial statement data was derived from audited financial statements and these financial statements do not include all the information and footnotes required for complete financial statements. These statements should be read in conjunction with the audited consolidated financial statements of the Company and the accompanying notes thereto for the year ended December 31, 2023.

These unaudited interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and nine months ended September 30, 2023 and 2024 are not necessarily indicative of results that can be expected for a full year. These unaudited interim condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2023.

All amounts expressed in these condensed consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” and “CAD” are to Canadian dollars.

3. Significant accounting policies

Use of estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Areas of significant estimates include, but are not limited to, revenue recognition including estimated timing of completion of performance obligations and determining whether an option for additional goods or services represents a material right, the impairment assessment of intangible assets and goodwill, and contingent consideration payable, and the estimates of stock-based compensation awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could significantly differ from those estimates.

Recent accounting pronouncements not yet adopted

The Company has reviewed recent accounting pronouncements and concluded that they are either not applicable to the Company or no material impact is expected in the condensed consolidated financial statements as a result of future adoption.

4. Net loss per share

Basic and diluted net loss per share was calculated as follows:


	Three months ended September 30,				Nine months ended September 30,
Basic and diluted loss per share	2023		2024		2023		2024
Net loss	$	(28,610)	$	(51,107)	$	(99,248)	$	(128,647)
Weighted-average common shares outstanding	289,496,841		294,851,945		288,750,387		293,930,702
Net loss per share - basic and diluted	$	(0.10)	$	(0.17)	$	(0.34)	$	(0.44)

The Company’s potentially dilutive securities, which include stock options and restricted share units (“RSUs”), have been excluded from the computation of diluted net loss per share for the three and nine months ended September 30, 2023 and September 30, 2024 as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding for the three and nine months ended September 30, 2023 and September 30, 2024 used to calculate both basic and diluted net loss per share is the same.

The Company excluded 50,081,069 and 50,544,294 potential common shares for the three and nine months ended September 30, 2023, and 58,027,706 and 58,543,314 potential common shares for the three and nine months ended September 30, 2024, from the computation of diluted net loss per share because including them would have had an anti-dilutive effect.

5. Property and equipment, net

Property and equipment, net consisted of the following:


	December 31, 2023		September 30, 2024
Computers	$	3,517	$	5,365
Land	53,405		53,405
Building	43,947		66,919
Laboratory equipment	70,350		79,486
Leasehold improvements	73,944		96,487
Operating lease right-of-use assets	73,141		68,319
Property and equipment	318,304		369,981
Less: accumulated depreciation	(30,608)		(38,718)
Property and equipment, net	$	287,696	$	331,263

As of December 31, 2023 and September 30, 2024, property and equipment includes leasehold improvements and construction in progress in the amount of $91.0 million and $93.0 million, respectively, and construction deposits of $13.7 million and $15.4 million, respectively, that have not commenced depreciation. Depreciation expense on property and equipment for the three and nine months ended September 30, 2023 was $3.1 million and $8.9 million, respectively, and $3.8 million and $10.4 million for the three and nine months ended September 30, 2024, respectively.

6. Intangible assets

Intangible assets consisted of the following:


	December 31, 2023			September 30, 2024
	Gross carrying amount	Accumulated amortization	Net book value	Gross carrying amount	Accumulated amortization	Net book value
License	38,433	26,861	11,572	38,433	28,723	9,710
Technology	52,700	7,857	44,843	52,700	9,833	42,867
IPR&D	64,010	–	64,010	—	–	–
	155,143	34,718	120,425	91,133	38,556	52,577

For the quarter ended September 30, 2024, the Company recorded a full impairment charge of the carrying value of $32.0 million (or $23.3 million, net of deferred income tax) associated with the IPR&D acquired through the 2020 acquisition of Trianni. The impairment was due to our ongoing internal program prioritization which resulted in the discontinuance of the development of the next-generation transgenic mice.

In the quarter ended June 30, 2024, the Company recorded a full impairment charge of the carrying value of $32.0 million (or $23.7 million, net of deferred income tax) associated with the IPR&D acquired through the 2021 acquisition of TetraGenetics. The impairment was a result of the Company's ongoing internal program prioritization. Details of a corresponding impact to contingent consideration associated with the TetraGenetics acquisition are disclosed in Note 11.

The impairments are reflected within Depreciation, amortization, and impairment expense.

Amortization expense on intangible assets subject to amortization is estimated to be as follows for each of the next five years ended September 30:


	Amortization Expense
2025	$	4,297
2026	4,297
2027	4,297
2028	4,297
2029	4,297
	$	21,485

7. Investments in equity accounted investees, and other long-term assets

The Company has entered into two separate 50% joint ventures, Dayhu JV and Beedie JV, as part of the construction of future office and laboratory headquarters. The Company recorded immaterial amounts of proportionate income or loss with respect to either venture in the three and nine months ended September 30, 2023 and 2024.

Dayhu JV

As of December 31, 2023 and September 30, 2024, the equity investment balance was $42.1 million and $42.8 million, respectively. Substantially all the assets in the Dayhu JV are comprised of property and equipment. As of December 31, 2023 and September 30, 2024, the Company recorded a right-of-use asset of $49.1 million and $49.5 million, respectively, and an operating lease liability of $50.4 million and $50.1 million, respectively, associated with an office lease with the Dayhu JV. In the three and nine months ended September 30, 2023, the Company incurred lease expense of $1.3 million and $4.0 million, respectively, and $1.3 million and $4.0 million in the three and nine months ended September 30, 2024, respectively, to the Dayhu JV included within operating expenses.

At December 31, 2023 and September 30, 2024, the Company had a loan receivable balance of CAD $45.9 million ($34.7 million) and CAD $46.3 million ($34.0 million), respectively, directly with our JV partner, Dayhu, included in other long-term assets.

Beedie JV

As of December 31, 2023 and September 30, 2024, the equity investment balance was $23.8 million and $41.2 million, respectively, of which substantially all the assets in the Beedie JV is comprised of property and equipment.

At December 31, 2023 and September 30, 2024, the Company had a loan receivable balance of CAD $18.4 million ($13.9 million) and CAD $40.4 million ($29.9 million), respectively, directly with our JV partner, Beedie, which relates to the land and construction loan and is included in other long-term assets.

8. Other current assets and liabilities

Other current assets


	December 31, 2023		September 30, 2024
Taxes receivable	$	33,792	$	31,863
Prepaid expenses and other	22,018		11,508
Total other current assets	$	55,810	$	43,371

Current accounts payable and other current liabilities


	December 31, 2023		September 30, 2024
Accounts payable and accrued liabilities	$	28,603	$	34,795
Current portion of operating lease liability	6,158		5,125
Payroll liabilities	7,707		5,992
Current portion of deferred government contribution	7,112		7,861
Total accounts payable and other current liabilities	$	49,580	$	53,773

9. Shareholders’ equity

The following table summarizes the Company’s stock option activity under the Pre-IPO Plan since December 31, 2023:


	Number of Shares	Weighted- Average Exercise Price
Outstanding as of December 31, 2023	30,647,575	$	0.94
Granted	–	–
Exercised	(3,380,807)	0.49
Forfeited	(3,750)	1.22
Outstanding as of September 30, 2024	27,263,018	$	0.99
Options exercisable as of September 30, 2024	25,985,445	$	0.95

The following table summarizes the Company’s stock option activity under the 2020 Plan since December 31, 2023:


	Number of Shares	Weighted- Average Exercise Price
Outstanding as of December 31, 2023	13,992,304	$	13.82
Granted	10,829,589	5.22
Exercised	–	–
Forfeited	(905,020)	11.80
Outstanding as of September 30, 2024	23,916,873	$	10.00
Options exercisable as of September 30, 2024	7,799,362	$	15.12

The following table summarizes the Company’s RSU activity under the 2020 Plan since December 31, 2023:


	Number of Shares	Weighted- Average Grant Date Fair Value
Outstanding as of December 31, 2023	4,075,590	$	11.61
Granted	4,080,053	5.28
Vested and settled	(951,697)	12.69
Forfeited	(356,131)	8.57
Outstanding as of September 30, 2024	6,847,815	$	7.85

As of September 30, 2024, the number of shares available for issuance under the 2020 Plan was 33,842,104, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020.

Stock-based compensation:

Stock-based compensation expense was classified in the condensed consolidated statements of loss and comprehensive loss as follows:


	Three months ended September 30,				Nine months ended September 30,
	2023		2024		2023		2024
Research and development	$	7,796	$	7,621	$	23,370	$	24,199
Sales and marketing	1,264		1,545		3,864		4,473
General and administrative	6,802		7,998		20,501		23,683
	$	15,862	$	17,164	$	47,735	$	52,355

10. Revenue

The disaggregated revenue categories are presented on the face of the condensed consolidated statements of loss and comprehensive loss. Deferred revenue outstanding in each respective period is as follows:


	December 31, 2022		September 30, 2023		December 31, 2023		September 30, 2024
Deferred revenue	$	41,128	$	33,890	$	27,153	$	13,678

During the three and nine months ended September 30, 2023, the Company recognized $4.1 million and $11.0 million, respectively, and $5.9 million and $18.9 million, respectively, in the three and nine months ended September 30, 2024, of revenue that had been included in deferred revenue as of December 31, 2022 and December 31, 2023.

11. Financial instruments

Fair Value Measurements

The Company categorizes its financial assets and liabilities measured at fair value into a three-level hierarchy established by U.S. GAAP that prioritizes those inputs to valuation techniques used to measure fair value based on the degree to which they are observable. The three levels of the fair value hierarchy are as follows: Level 1 inputs are quoted prices in active markets for identical assets and liabilities; Level 2 inputs, other than quoted prices included within Level 1, are observable for the asset or liability either directly or indirectly; and Level 3 inputs are not observable in the market.

The Company’s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, accounts receivable, loans receivable, accounts payable and other liabilities, and contingent consideration payable. The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and other liabilities, and loans receivable approximate their fair values, and are primarily classified as Level 2.

At September 30, 2024, the Company also held non-marketable securities included in other long term assets of $32.3 million (December 31, 2023 - $32.3 million). These non-marketable securities are measured at cost less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. In the quarter ended September 30, 2024, one of the Company's non-marketable securities was disposed of, resulting in a recognized gain of $16.5 million reflected within other income.

Contingent Consideration

Contingent consideration related to business acquisitions is recorded at fair value on the acquisition date and adjusted on a recurring basis for changes in its fair value. Changes in the fair value of contingent consideration liabilities can result from changes in anticipated payments and changes in assumed discount periods and rates. These inputs are unobservable in the market and are therefore categorized as Level 3 inputs. There were no changes to the valuation technique and inputs used in these fair value measurements since acquisition.

The following table presents the changes in fair value of the liability for contingent consideration:


Three Months Ended September 30, 2024	Liability at beginning of the period		Increase in fair value of liability for contingent consideration		Liability at end of the period
Trianni (i)	$	20,027	$	190	$	20,217
TetraGenetics (ii)	$	4,441	$	–	$	4,441


Nine Months Ended September 30, 2024	Liability at beginning of the period		Increase (decrease) in fair value of liability for contingent consideration		Liability at end of the period
Trianni (i)	$	18,697	$	1,520	$	20,217
TetraGenetics (ii)	$	36,691	$	(32,250)	$	4,441

i)The estimated fair value of the earn-out payments relates to a specific customer license and the fair value was determined by estimating the payout of the expected future net cash flows associated to the specific customer license during the earn-out period. The significant assumptions inherent in the development of the value include the amount and timing of projected future net revenues received by us from the specific customer license, and the discount rate selected to measure the risks inherent in the future cash flows, which was approximately 22.0%.

ii)The estimated fair value of potential future successful milestone payouts was determined by estimating the expected future cash flows associated with the potential milestone events. The significant assumptions include the amount and timing of projected future cash flows, risk adjusted for various factors including probability of success, discounted at 12.8%, the rate that measures the risks inherent in the future cash flows. In the quarter ended June 30, 2024, the fair value of the contingent consideration was adjusted to reflect the expected value of the Company's ongoing internal program prioritization, resulting in a reduction of $32.4 million recognized as a non-cash fair value gain through other income.

In-Process Research and Development Assets

As discussed in Note 6, the estimated fair values in support of the TetraGenetics full impairment charge were categorized within Level 3 of the fair value hierarchy and were determined using an income-based approach, which was based on a probability-adjusted present value of the future estimated after-tax cash flows attributable to the intangible assets. The significant assumptions inherent in estimating the fair values, from the perspective of a market participant, include a probability-adjusted success rate of its continued development through to clinical trials, future revenue, operating and development costs, milestone and regulatory success, obsolescence, and profitability. A de-risked discount rate of 12.8% for TetraGenetics was used to present value the probability of success risk adjusted after-tax cash flows attributable to the IPR&D.

Marketable Securities

As part of the Company’s cash management strategy, the Company holds high credit quality marketable securities that are available to support the Company’s current operations. As of September 30, 2024, our marketable securities were rated A- or higher (or its equivalent) by at least two of the major rating agencies with a weighted average life of approximately 0.5 years.

Level 2 marketable securities in the fair value hierarchy were based on quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. There were no transfers between Level 1, Level 2 and Level 3 during the period.

The following table presents information about the Company’s marketable securities that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values:


	Fair Value Measurements at September 30, 2024:
	Level 1		Level 2		Level 3		Total
Marketable securities
U.S. government agencies	$	113,838	$	–	$	–	$	113,838
Certificate of deposit	–		120,297		–		120,297
Commercial paper	–		48,484		–		48,484
Corporate bonds	–		128,973		–		128,973
Asset backed securities	–		104,907		–		104,907
	$	113,838	$	402,661	$	–	$	516,499

12. Commitments and contingencies

From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company does not have contingency reserves established for any litigation liabilities and any of the costs related to such legal proceedings are expensed as incurred.

The Company may enter into certain agreements with strategic partners in the ordinary course of operations that may include investments in collaborative arrangements, contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements.

Pursuant to the agreements, the Company may be obligated to make research and development and regulatory milestone payments upon the occurrence of certain events and upon receipt of royalty payments in the low single-digits to mid-twenties based on certain net sales targets. No amounts were expensed during the three and nine months ended September 30, 2023 or September 30, 2024.

13. Government contributions

Government Contribution 1

In May of 2020, the Company received a funding commitment from the Government of Canada under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) for a total of CAD $175.6 million ($125.6 million), collectively "Government Contribution 1" which is intended to support research and development efforts related to the discovery of antibodies to treat COVID-19, and to build technology and manufacturing infrastructure for antibody therapeutics against future pandemic threats. From inception to September 30, 2024, the Company incurred CAD $169.4 million ($130.2 million) in expenditures in respect of the Canadian government's Strategic Innovation Fund (SIF), of which CAD $58.7 million ($46.1 million) and CAD $110.7 million ($84.1 million) relate to phase 1 and 2, respectively as defined in the agreement. Spending under phase 1 of the agreement and such amounts are non-repayable, while repayment on phase 2 of the funding is conditional on achieving certain revenue thresholds over a specified period of time as prescribed in the agreement. As of September 30, 2024, no amounts have been accrued related to the repayment terms.

Government Contribution 2

In May of 2023, the Company entered into multi-year contribution agreements with the Government of Canada and the Government of British Columbia for a total of CAD $300.0 million ($222.3 million), collectively "Government Contribution 2." These investments are intended to build new capabilities in Canada to develop, manufacture, and deliver antibody medicines to patients through Phase 1 clinical trials and build expertise in translational science, technical operations, and clinical operations and research.

The Government of Canada has committed up to CAD $225.0 million ($166.7 million) of which CAD $56.2 million ($41.6 million) is non-repayable, CAD $78.8 million ($58.4 million) is repayable and CAD $90.0 million ($66.7 million) is conditionally repayable. Both the repayable and conditionally repayable amounts are repayable starting in 2033. The repayable funding is payable over fifteen years and the conditionally repayable portion repaid is based on a computed percentage rate of the Company’s revenue over a period of up to fifteen years, at a factor of up to 1.4 times the original conditionally repayable grant. The agreement will expire on the later of April 30, 2047, or the date of the last repayment, unless earlier terminated. From inception to September 30, 2024, the Company has recorded CAD $57.2 million ($42.4 million) in respect of the funding.

The Government of British Columbia has committed up to CAD $75.0 million ($55.6 million) which includes partial reimbursement of certain eligible expenditures up to CAD $37.5 million ($27.8 million) towards eligible infrastructure investments paid over five years; and a CAD $37.5 million ($27.8 million) conditional portion paid upon achievement of certain defined milestones, including upon the Company’s undertaking of certain clinical trial activities in British Columbia. Up to a maximum of CAD $64.0 million ($48.0 million) may become payable starting in 2032, over up to fifteen years, conditional to the Company achieving revenue exceeding a given threshold. The agreement will expire on the earlier of 2047, or the date of the last payment, unless earlier terminated, as prescribed in the agreement. From inception to September 30, 2024, the Company has recorded CAD $37.2 million ($27.6 million) in respect of the funding commitment.

Impact to Consolidated Financial Statements

The Company recognized the following on the consolidated balance sheets:


	September 30, 2024
			Deferred Government Contribution
	Accounts Receivable		Government Grant1						Total
			Non-repayable		Conditionally Repayable2		Repayable
Government Contribution 1 (Canada)	$	13,378	$	6,558	$	76,046	$	–	$	82,604
Government Contribution 2 (Canada)	16,176		6,735		–		32,629		39,364
Government Contribution 2 (British Columbia)	22,575		–		26,952		–		26,952
Other Government Grants	–		987		–		–		987
September 30, 2024	$	52,129	$	14,280	$	102,998	$	32,629	$	149,907
December 31, 2023	$	36,051	$	14,811	$	71,796	$	16,420	$	103,027

September 30, 2024
Current	$	27,053	$	4,351	$	3,510	$	–	$	7,861
Long-term	$	25,076	$	9,929	$	99,488	$	32,629	$	142,046

1 Government Contributions are amortized into other income over the weighted average life of approximately 8 years.

2 No amounts have been accrued related to the repayment terms as the conditions are estimated to be non-probable.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings “Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Forward-looking statements can often be identified by the use of terminology such as “subject to”, “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. In particular, these forward-looking statements include, but are not limited to:

•our expectations regarding the rate and degree of market acceptance of our antibody discovery and development engine;

•companies and technologies in our industry that compete with our business;

•our ability to manage and grow our business by introducing our antibody discovery and development engine to new partners and expanding our relationships with existing partners;

•our expectations regarding the quality of our antibody discovery and development engine and technological capabilities, the advancement of internal programs, and their acceptance by new and existing partners in our industry;

•our operating results and financial performance;

•our partners’ ability to achieve projected discovery and development milestones and other anticipated key events, including commercial sales resulting in royalties owed to us, in the expected timelines or at all;

•our ability to provide our partners with a full solution from target identification to investigational new drug, or Investigational New Drug ("IND"), application submission;

•our partners’ ability to develop and commercialize a molecule discovered by us, on a timely basis or at all;

•our expectations regarding the completion of our good manufacturing practices, or GMP, facility and our manufacturing capabilities;

•our ability to establish and maintain intellectual property protection for our technologies and workflows and avoid or defend against claims of patent infringement;

•our ability to attract, hire and retain key personnel and to manage our personnel growth effectively;

•our ability to obtain additional financing in future offerings;

•the volatility of the trading price of our common shares;

•business disruptions affecting our operations and the development of our antibody discovery and development engine;

•our ability to avoid material weaknesses or significant deficiencies in our internal control over financial reporting in the future;

•our expectations regarding our Passive Foreign Investment Company, or PFIC, status for our taxable year ended December 31, 2024, or any future taxable year;

•our expectations regarding the use of our cash resources;

•our expectations about market trends; and

•our ability to predict and adapt to government regulation.

We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements. We have included important

factors in the cautionary statements included in this Quarterly Report, particularly in “Summary of the Material and Other Risks Associated with Our Business” above and “Risk Factors” below, that we believe could cause actual results or events to differ materially from our forward-looking statements. We operate in a competitive and rapidly changing environment and new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments we may make or enter.

Additionally, inflation generally affects us by increasing our employee-related costs and certain other expenses. Our financial condition and results of operations may also be impacted by other factors we may not be able to control, such as global supply chain disruptions, uncertain global economic conditions, global trade disputes or political instability as further discussed in the section “Risk Factors” in this Quarterly Report.

You should read this Quarterly Report and the documents that we file with the Securities and Exchange Commission, or the SEC, with the understanding that our actual future results may differ materially from what we expect. The forward-looking statements contained in this Quarterly Report are made as of the date of this Quarterly Report, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

This Quarterly Report includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties as well as our own estimates of potential market opportunities. All market data used in this Quarterly Report involves assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.

We express all amounts in this Quarterly Report on Form 10-Q in U.S. dollars, except where otherwise indicated. References to “$” and “US$” are to U.S. dollars and references to “C$” and “CAD$” are to Canadian dollars.

Except as otherwise indicated, references in this Quarterly Report on Form 10-Q to “AbCellera,” the “Company,” “we,” “us” and “our” refer to AbCellera Biologics Inc. and its consolidated subsidiaries.

Overview

We are a team of scientists, engineers, creatives, and business professionals addressing the barriers of conventional antibody drug development. We believe investments in technology will improve the quality, speed, and success of drug development and that long-term value creation begins with building a great company that can create multiple products, repeatedly and successfully. To maximize the value and impact of our work, we are advancing a pipeline of programs and strategically partnering with groups with novel science or innovative technology.

We focus on the development of antibody-based drugs and are committed to improving discovery and development. We aim to build a competitive advantage in bringing antibody therapeutics from target into clinical testing by combining expertise, technologies, and infrastructure to build an integrated engine for antibody drug discovery and development. We think deeply about capital allocation and strive to maximize long-term value while mitigating the risks that are inherent in drug development and in scaling a company. We look for opportunities where we believe low-risk investments in building technology and operational efficiency can create a sustained competitive advantage and drive long-term value by making biologics drug development faster and more efficient.

We structure our agreements in a way that is designed to align our partners’ economic interests with our own. We deliberately partner with companies of all sizes to propel programs pursuing the best ideas for new antibody-based drugs to the clinic, together. We enable discovery against targets that have traditionally been intractable, and we accelerate programs against less difficult targets.

As our capabilities have grown, we are also strategically leveraging our engine to develop internal programs to address areas of high unmet medical need and to advance our pipeline of first-in-class and best-in-class medicines.

Our deals emphasize participation in the success and upside of future antibody therapeutic candidates. Our partnership agreements include near-term payments for technology access, research and intellectual property rights, and downstream payments in the form of clinical and commercial milestones, and royalties on net sales. We also participate in alternative investment opportunities including equity in our business partners and various rights for deeper involvement in moving molecules forward. Longer-term, we are eligible to receive additional payments upon satisfaction of clinical and commercial milestones, which we refer to as milestone payments, as well as royalties on sales of approved products derived from antibodies that we discover for our partners. Our partnerships generally include royalty payments (or equivalents) on net sales. For discovery agreements, these are typically in the single-digit to low-double digit range. We believe that our internal programs, if successfully out-licensed, may generate substantial upfront payments and royalty positions on net sales in the high single-digits to high teens range, in addition to clinical and commercial milestones.

We focus a substantial portion of our resources on research and development efforts towards strengthening our discovery and development engine and developing a pipeline of internal and co-development programs. We expect to continue to make significant investments in this area for the foreseeable future, over time shifting effort from engine development towards engine application. We expect to continue to incur significant expenses in connection with our ongoing activities, including as we:

•invest in research and development activities to improve our antibody discovery and development engine including investments in completing the construction of our small-scale manufacturing facility and our new headquarters through our joint ventures;

•pursue internal and co-development programs in preclinical and eventually clinical development;

•market and sell our solutions to existing and new strategic partners;

•expand and enhance operations to deliver programs, including investments in manufacturing;

•acquire businesses or technologies to support the growth of our business;

•attract, hire and retain qualified personnel; and

•continue to establish, protect and defend our intellectual property and patent portfolio, including our ongoing litigation.

To date, we have financed our operations primarily from revenue from our antibody discovery partnerships in the form of royalty revenue, government funding from grants, and from the issuance and sale of convertible preferred shares and notes, and common shares. Additionally, we have twice secured significant government co-investments in the form of non-dilutive capital to help fund research and development, including internal programs, and facility construction.

The Company has advanced two AbCellera-led programs into IND-enabling studies. The programs align with the Company's strategy of building value, both through strategic partnerships, and through internal discovery and development of potential first-in-class and best-in-class antibody therapies. We have started a cumulative total of 95 partner-initiated programs with downstream participation and have seen a cumulative total 14 molecules advanced into the clinic, as illustrated by the following chart.

Financial Highlights

The following table summarizes our key operating results for the three and nine months ended September 30, 2023 and September 30, 2024. All figures are in U.S. dollars and amounts are expressed in thousands, except loss per share data:


	Three months ended September 30,				Nine Months Ended September 30,
Financial Performance	2023		2024		2023		2024
Revenue:
Research fees	$	6,413	$	6,289	$	26,812	$	21,516
Licensing revenue	186		218		784		767
Milestone payments	–		–		1,250		1,500
Total revenue	6,599		6,507		28,846		23,783
Operating expenses:
Research and development(1)	37,917		40,969		127,036		121,183
Other operating expenses	23,572		59,201		72,964		144,611
Total operating expenses	61,489		100,170		200,000		265,794
Loss from operations	(54,890)		(93,663)		(171,154)		(242,011)
Total other income	(15,614)		(31,031)		(45,727)		(88,445)
Net loss before income tax	(39,276)		(62,632)		(125,427)		(153,566)
Net loss	$	(28,610)	$	(51,107)	$	(99,248)	$	(128,647)
Net loss per share
Basic	$	(0.10)	$	(0.17)	$	(0.34)	$	(0.44)
Diluted	$	(0.10)	$	(0.17)	$	(0.34)	$	(0.44)
Operating expenses include stock-based compensation:
Research and development	$	7,796	$	7,621	$	23,370	$	24,199
Sales and marketing	1,264		1,545		3,864		4,473
General and administrative	6,802		7,998		20,501		23,683

Financial Position and Liquidity					December 31, 2023		September 30, 2024
Cash and cash equivalents					133,320		126,640
Marketable securities					627,265		516,499
Total cash, cash equivalents, and marketable securities					760,585		643,139
Total assets					1,488,094		1,392,828
Total shareholders' equity					1,152,318		1,078,094

(1)Exclusive of depreciation, amortization, and impairment

Key Factors Affecting Our Results of Operations and Future Performance

We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by multiple factors as described below, each of which presents growth opportunities for our business. These factors also pose important challenges that we must successfully address to sustain our growth and improve our results of operations. Our ability to successfully address these challenges is subject to various risks and uncertainties, including those described in Part II, Item 1A, Risk Factors.

•Engaging with strategic partners. Our potential to grow revenue, in both the near and long term, is dependent on successfully engaging with strategic partners. For existing strategic partners, we seek to expand our relationships with them to collaborate on additional programs initiated by them as well as to create a basis for potentially out-licensing some of our internal programs. Our teams are selective in determining which partners we choose to engage with, focusing on the opportunities with the strong potential to generate significant value in the long term.

•Our partners successfully developing and commercializing the antibodies that we discover. We estimate that, based on the terms of our existing contracts and estimates of historical rates of success of antibody drug development, the vast majority of the potential value for each program is represented by potential future milestone

payments and royalties rather than research fees. As a result, we believe our business and our future results of operations will be highly reliant on the degree to which our partners successfully develop and commercialize the antibodies that we discover based on contracts with our partners. As our partners continue to advance development of the antibodies that we have discovered, we expect to start receiving additional milestone payments and royalties if any partners commence commercial sales of such antibodies.

•Rate and timing of selecting and initiating discovery projects by our partners. Once programs are secured under contract, partners must propose targets and agree on a detailed statement of work before we commence discovery research on any antibodies. The rate and timing of such selection and initiation differs from partner to partner. Research fees that we recognize under our partnerships depend on our delivery of antibodies for development by our partners and delays by our partners in selecting targets and agreeing on statements of work will impact revenue recognition.

•Successfully out-licensing drug candidates from our internal programs. We believe that our internal programs may result in drug candidates of interest to other drug developers with capabilities complimentary to our own. Where these capabilities can be expected to enhance the value of our drug candidate, we may seek to out-license. Successful out-licensing agreements could generate substantial up-front payments in addition to later milestone payments and royalties. Our financial performance may therefore be impacted by our ability to produce and out-license such drug candidates from our internal programs.

•Investing in enhancements to our discovery and development engine. Our ability to maintain and expand our partnerships is dependent on the advantages our discovery and development engine delivers to our partners and our internal programs. We intend to maintain our leading position through investments in research and development to refine and add capabilities in areas such as computation, protein engineering, immunization technologies, genetically engineered rodents and cell line selection. Specifically, we are currently completing our investments in integrated preclinical development and antibody manufacturing. We have also successfully executed and will continue to look for strategic technology acquisitions to improve, broaden and deepen our capabilities and expertise in antibody discovery and development, or those that offer opportunities to expand our business into adjacent therapeutic modalities. We intend to continue to devote resources to continue to improve our discovery differentiation which will impact our financial performance.

•Pursuing drug discovery and development opportunities internally. As the capabilities of our discovery and development engine have matured we are increasingly in a position to pursue attractive, well-validated targets ourselves, e.g. in the GPCR, ion channel, and TCE spaces. Such programs have the potential to yield first-in-class drug candidates in indications with substantial unmet medical need which we would wholly own. We plan on investing significant resources in the preclinical and, eventually, clinical development of internal programs which will impact our financial results. The investments in each program are undertaken at risk and may ultimately not yield a return.

Key Business Metrics

We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops as further described below with respect to changes in this and upcoming reports.


Cumulative Metrics	September 30, 2023	September 30, 2024	Change %
Partner-initiated program starts with downstreams	84	95	13	%
Molecules in the clinic	10	14	40	%

The table below outlines the details of molecules in the clinic as of September 30, 2024:

Molecule

Most advanced stage

Partner

Therapy areas

Program type

Bamlanivimab (LY-CoV555)

Marketed, EUA*

Eli Lilly and Company

Infectious disease – COVID-19

AbCellera-initiated; partner-led

Bebtelovimab (LY-CoV1404)

Marketed, EUA*

Eli Lilly and Company

Infectious disease – COVID-19

AbCellera-initiated; partner-led

TAK-920/DNL919

Phase 1*

Denali Therapeutics Inc.

Neurology - Alzheimer's Disease